The intervention on aging system: A classification model, the requirement for five novel categories

Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and...

Full description

Saved in:
Bibliographic Details
Published inAging medicine Vol. 5; no. 1; pp. 68 - 72
Main Author Palmer, Raymond D.
Format Journal Article
LanguageEnglish
Published Australia John Wiley & Sons, Inc 01.03.2022
John Wiley and Sons Inc
Wiley
Subjects
Aging
aging, experimental, gerontology, health industry, longevity industry
Biomarkers
Classification
Diet
Dietary minerals
Disease prevention
DNA methylation
Exercise
Fasting
Genomes
Lifestyles
Mortality
Review
Vitamins
aging, experimental, gerontology, health industry, longevity industry
Online AccessGet full text
ISSN2475-0360
2475-0360
DOI10.1002/agm2.12193

Cover

Abstract Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity‐based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole. The upward curve reflects the vision for humanity to pursue healthier living.
AbstractList Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity‐based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole. The upward curve reflects the vision for humanity to pursue healthier living.
Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity‐based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole. The upward curve reflects the vision for humanity to pursue healthier living.
Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity-based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole.
Abstract Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity‐based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole.
Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity-based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole.Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of reach technologies. However, longevity therapies such as stem cell replacement, fasting, gene therapies, fasting mimetics such as metformin and rapamycin, regulation and tissue reprogramming with OSK transcription factors, blood dilution, metabolic pathway engineering, reversal of epigenetic drift, heterochronic parabiosis, coenzyme replacement technologies (nicotinamide adenine dinucleotide) and a plethora of other established sciences are showing great potential at slowing down the rate at which tissues enter dysfunction. Recent discoveries have shed light on major mysteries of the aging process. Longevity-based discoveries are not only landing quickly, but therapies to prevent or reverse those drivers of aging are also being devised regularly and this is opening up an entirely new industry, the longevity industry. This presents the requirement for a new classification system where subjects can be divided into specific groups based on their potential for mortality. This system also enables the public to target which class of this classification system they wish to be on. Moving the population on the classification system to become more disease resistant holds great benefit for society and governments as a whole.
Author Palmer, Raymond D.
AuthorAffiliation 1 Science of Aging South Perth WA Australia
2 Full Spectrum Biologics & Health Sciences WA Australia
AuthorAffiliation_xml – name: 2 Full Spectrum Biologics & Health Sciences WA Australia
– name: 1 Science of Aging South Perth WA Australia
Author_xml – sequence: 1
  givenname: Raymond D.
  orcidid: 0000-0003-1898-0935
  surname: Palmer
  fullname: Palmer, Raymond D.
  email: ray.palmer@me.com
  organization: Full Spectrum Biologics & Health Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35309156$$D View this record in MEDLINE/PubMed
BookMark eNp9kd1q3DAQhU1JaX6amz5AMfSmpN10JEv-yUVhCW0aSOnN3gtZHnu1yNJGsjfs2_RZ-mTVrtOQhBIQSIy-OZw5c5wcWGcxSd4ROCcA9IvsenpOKKmyV8kRZQWfQZbDwaP3YXIawgoASFVVeUbfJIcZz6AiPD9KmsUSU20H9Bu0g3Y2jUd22nZp2IYB-4t0niojQ9CtVnJP9K5B8zkdlvjnt8fbUXvsY3PaOp-2eoOpdRs0aaSxc15jeJu8bqUJeHp_nySL798Wlz9mN7-uri_nNzPFCctmBEuKXCFrScFybBrWAgelCsi4orRqiaylzAkrAfI4XQltWWccqprVqiDZSXI9yTZOrsTa6176rXBSi33B-U5IP2hlUORxfIKsAloqJhXUBWtqqrisapUDY1Hr06Q12rXc3kljHgQJiF3yYpe82Ccf6a8TvR7rHhsV0_DSPLHw9MfqpejcRpQVKSgvosDHewHvbkcMg-h1UGiMtOjGIGjOSMwoL2hEPzxDV270NuYaqawkBSF85__9Y0cPVv5tPgIwAcq7EDy2Qulhv99oUJv_T3n2rOXFSMgE32mD2xdIMb_6Saeev4d83q0
CitedBy_id crossref_primary_10_18632_aging_206221
Cites_doi 10.1038/S41591‐019‐0673‐2
10.1038/s41586‐018‐0645‐6
10.1016/j.cub.2018.04.015
10.1016/0891‐5849(94)90080‐9
10.1016/J.MOLCEL.2016.01.028
10.1089/rej.2017.2024
10.1186/S13287‐019‐1165‐5
10.1093/JN/134.3.489
10.1016/j.cmet.2018.02.011
10.1016/J.COI.2013.06.002
10.1111/ACEL.13028
10.1016/j.cmet.2016.05.022
10.3390/genes9030165
10.3389/FPUBH.2017.00335
10.1016/J.CHEMBIOL.2009.12.001
10.1016/J.JACC.2018.04.020
10.18632/aging.101590
10.1073/pnas.1814723116
10.1042/BST0321006
10.1159/000484629
10.7326/M19‐0341
10.1038/nrm.2016.93
10.1016/S0891‐5849(00)00317‐8
10.18632/aging.103418
10.1371/journal.pone.0057709
10.3390/nu11061251
10.18632/AGING.101960
10.1093/GERONA/GLT190
10.1038/s41586‐020‐2975‐4
10.1016/j.cell.2012.01.003
10.3390/ANTIOX4040793
10.1080/15592294.2015.1013792
10.7326/L14‐5001‐8
10.1016/j.cmet.2015.09.008
10.1002/agm2.12170
10.1007/978‐981‐13‐2835‐0_9
10.1089/ARS.2017.7269
10.1126/science.aac4854
10.2217/epi.11.22
10.18203/2349‐3259.IJCT20161408
10.1093/CARCIN/BGV031
10.1091/mbc.E18‐10‐0650
10.1017/S0029665111003302
10.3109/03014460.2013.807878
10.7326/0003‐4819‐142‐1‐200501040‐00110
10.1016/j.arr.2016.10.005
10.1016/J.ARR.2019.02.003
ContentType Journal Article
Copyright 2022 The Authors. published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
2022 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
– notice: 2022 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
– notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1002/agm2.12193
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Proquest Health and Medical Complete
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

PubMed

Publicly Available Content Database
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals - NZ
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: 7X7
  name: Proquest Health and Medical Complete
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate PALMER
EISSN 2475-0360
EndPage 72
ExternalDocumentID oai_doaj_org_article_60911e49028c4ac0b74db2c5a9bc6044
10.1002/agm2.12193
PMC8917257
35309156
10_1002_agm2_12193
AGM212193
Genre reviewArticle
Journal Article
Review
GroupedDBID 0R~
1OC
24P
7X7
8FI
8FJ
AAHHS
ABUWG
ACCFJ
ACCMX
ACGFS
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
ADZOD
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
EBS
EIHBH
EJD
FYUFA
GROUPED_DOAJ
HMCUK
M~E
O9-
OK1
OVD
OVEED
PIMPY
PQQKQ
PROAC
RPM
TEORI
UKHRP
WIN
AAMMB
AAYXX
AEFGJ
AGXDD
AIDQK
AIDYY
CITATION
PHGZM
PHGZT
PUEGO
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c5143-1e82e5ce4f1746edd4f050cc7035c229f1abaa614800647580f8b3509b4bc713
IEDL.DBID UNPAY
ISSN 2475-0360
IngestDate Wed Aug 27 01:27:42 EDT 2025
Sun Sep 07 11:17:28 EDT 2025
Tue Sep 30 16:18:38 EDT 2025
Fri Sep 05 04:36:47 EDT 2025
Fri Jul 25 04:18:47 EDT 2025
Mon Jul 21 06:05:04 EDT 2025
Wed Oct 01 03:17:59 EDT 2025
Thu Apr 24 22:59:28 EDT 2025
Wed Jan 22 16:25:54 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords aging, experimental, gerontology, health industry, longevity industry
Language English
License Attribution-NonCommercial-NoDerivs
2022 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5143-1e82e5ce4f1746edd4f050cc7035c229f1abaa614800647580f8b3509b4bc713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-1898-0935
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.1002/agm2.12193
PMID 35309156
PQID 2638171154
PQPubID 4365298
PageCount 5
ParticipantIDs doaj_primary_oai_doaj_org_article_60911e49028c4ac0b74db2c5a9bc6044
unpaywall_primary_10_1002_agm2_12193
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8917257
proquest_miscellaneous_2641514672
proquest_journals_2638171154
pubmed_primary_35309156
crossref_citationtrail_10_1002_agm2_12193
crossref_primary_10_1002_agm2_12193
wiley_primary_10_1002_agm2_12193_AGM212193
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2022
PublicationDateYYYYMMDD 2022-03-01
PublicationDate_xml – month: 03
  year: 2022
  text: March 2022
PublicationDecade 2020
PublicationPlace Australia
PublicationPlace_xml – name: Australia
– name: Milton
– name: Hoboken
PublicationTitle Aging medicine
PublicationTitleAlternate Aging Med (Milton)
PublicationYear 2022
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2017; 5
2017; 20
2018; 28
2015; 36
2000; 29
2021; 4
2013; 25
2015; 4
2019; 51
2019; 30
2019; 11
2019; 10
2013; 40
2018; 563
2015; 10
2020; 588
2014; 69
2019; 18
2020; 12
2012; 148
2016; 17
2013; 8
2011; 3
2018; 64
2018; 27
2005; 25
2015; 350
2004; 32
2004; 134
2012; 71
2018; 9
2005; 142
2016; 3
2017; 39
2015; 22
2019; 25
2019; 116
2018; 90
2016; 61
2018; 71
2014; 160
1994; 17
2019; 171
2018; 10
2009; 16
2016; 23
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
Bekaert S (e_1_2_9_10_1) 2005; 25
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_42_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_21_1
e_1_2_9_46_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_23_1
e_1_2_9_44_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_27_1
e_1_2_9_48_1
e_1_2_9_29_1
References_xml – volume: 4
  start-page: 793
  issue: 4
  year: 2015
  end-page: 810
  article-title: Which is the most significant cause of aging?
  publication-title: Antioxidants
– volume: 39
  start-page: 46
  year: 2017
  end-page: 58
  article-title: Impact of intermittent fasting on health and disease processes
  publication-title: Ageing Res Rev
– volume: 36
  start-page: S61
  issue: Suppl 1
  year: 2015
  end-page: S88
  article-title: Causes of genome instability: the effect of low dose chemical exposures in modern society
  publication-title: Carcinogenesis
– volume: 23
  start-page: 965
  issue: 6
  year: 2016
  end-page: 966
  article-title: Why NAD+ declines during aging: it's destroyed
  publication-title: Cell Metab
– volume: 142
  start-page: 37
  issue: 1
  year: 2005
  publication-title: Ann Intern Med
– volume: 134
  start-page: 489
  issue: 3
  year: 2004
  end-page: 492
  article-title: Glutathione metabolism and its implications for health
  publication-title: J Nutr
– volume: 3
  start-page: 37
  issue: 2
  year: 2016
  end-page: 46
  article-title: In silico clinical trials: how computer simulation will transform the biomedical industry
  publication-title: Int J Clin Trials
– volume: 148
  start-page: 46
  issue: 1–2
  year: 2012
  end-page: 57
  article-title: Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock
  publication-title: Cell
– volume: 32
  start-page: 1006
  year: 2004
  end-page: 1007
  article-title: Folate and DNA methylation during in utero development and aging
  publication-title: Biochem Soc Trans
– volume: 12
  start-page: 8790
  issue: 10
  year: 2020
  end-page: 8819
  article-title: Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline‐albumin
  publication-title: Aging
– volume: 51
  start-page: 1
  year: 2019
  end-page: 10
  article-title: Telomere length and health outcomes: an umbrella review of systematic reviews and meta‐analyses of observational studies
  publication-title: Ageing Res Rev
– volume: 588
  start-page: 124
  issue: 7836
  year: 2020
  end-page: 129
  article-title: Reprogramming to recover youthful epigenetic information and restore vision
  publication-title: Nature
– volume: 563
  start-page: 354
  issue: 7731
  year: 2018
  end-page: 359
  article-title: De novo NAD+ synthesis enhances mitochondrial function and improves health
  publication-title: Nature
– volume: 64
  start-page: 127
  issue: 2
  year: 2018
  end-page: 134
  article-title: mTOR as regulator of lifespan, aging, and cellular senescence: a mini‐review
  publication-title: Gerontology
– volume: 116
  start-page: 1207
  issue: 4
  year: 2019
  end-page: 1212
  article-title: Leading a meaningful life at older ages and its relationship with social engagement, prosperity, health, biology, and time use
  publication-title: Proc Natl Acad Sci USA
– volume: 20
  start-page: 430
  issue: 5
  year: 2017
  end-page: 436
  article-title: Epigenetic drift is a determinant of mammalian lifespan
  publication-title: Rejuvenation Res
– volume: 16
  start-page: 1219
  issue: 12
  year: 2009
  end-page: 1223
  article-title: Telomeres and telomerase: from discovery to clinical trials
  publication-title: Chem Biol
– volume: 9
  start-page: 165
  issue: 3
  year: 2018
  article-title: Targeting mitochondria to counteract age‐related cellular dysfunction
  publication-title: Genes
– volume: 350
  start-page: 1208
  issue: 6265
  year: 2015
  end-page: 1213
  article-title: NAD+ in aging, metabolism, and neurodegeneration
  publication-title: Science
– volume: 71
  start-page: 2570
  issue: 22
  year: 2018
  end-page: 2584
  article-title: Supplemental vitamins and minerals for CVD prevention and treatment
  publication-title: J Am Coll Cardiol
– volume: 5
  start-page: 335
  year: 2017
  article-title: Age‐related diseases and clinical and public health implications for the 85 years old and over population
  publication-title: Front Public Health
– volume: 25
  start-page: 3011
  issue: 4
  year: 2005
  end-page: 3021
  article-title: Telomere attrition as ageing biomarker
  publication-title: Anticancer Res
– volume: 28
  start-page: 1714
  issue: 11
  year: 2018
  end-page: 1724.e4
  article-title: Short‐term, intermittent fasting induces long‐lasting gut health and TOR‐independent lifespan extension
  publication-title: Curr Biol
– volume: 29
  start-page: 222
  issue: 3–4
  year: 2000
  end-page: 230
  article-title: Mitochondrial free radical generation, oxidative stress, and aging
  publication-title: Free Radic Biol Med
– volume: 61
  start-page: 654
  issue: 5
  year: 2016
  end-page: 666
  article-title: The mitochondrial basis of aging
  publication-title: Mol Cell
– volume: 10
  start-page: 179
  issue: 3
  year: 2015
  end-page: 190
  article-title: Epigenetic effects of selenium and their implications for health
  publication-title: Epigenetics
– volume: 10
  start-page: 68
  issue: 1
  year: 2019
  article-title: Stem cells: past, present, and future
  publication-title: Stem Cell Res Ther
– volume: 17
  start-page: 679
  issue: 11
  year: 2016
  end-page: 690
  article-title: Slowing ageing by design: the rise of NAD+ and sirtuin‐activating compounds
  publication-title: Nat Rev Mol Cell Biol
– volume: 25
  start-page: 1843
  issue: 12
  year: 2019
  end-page: 1850
  article-title: Undulating changes in human plasma proteome profiles across the lifespan
  publication-title: Nat Med
– volume: 69
  start-page: 779
  issue: 7
  year: 2014
  end-page: 789
  article-title: Glycans are a novel biomarker of chronological and biological ages
  publication-title: J Gerontol A Biol Sci Med Sci
– volume: 10
  start-page: 2832
  issue: 10
  year: 2018
  end-page: 2854
  article-title: A multi‐tissue full lifespan epigenetic clock for mice
  publication-title: Aging
– volume: 3
  start-page: 267
  issue: 3
  year: 2011
  end-page: 277
  article-title: Epigenetics and lifestyle
  publication-title: Epigenomics
– volume: 11
  start-page: 1251
  issue: 6
  year: 2019
  article-title: Slowing down ageing: the role of nutrients and microbiota in modulation of the epigenome
  publication-title: Nutrients
– volume: 18
  issue: 6
  year: 2019
  article-title: Reversal of epigenetic aging and immunosenescent trends in humans
  publication-title: Aging Cell
– volume: 30
  start-page: 2584
  issue: 20
  year: 2019
  end-page: 2597
  article-title: NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival
  publication-title: Mol Biol Cell
– volume: 71
  start-page: 75
  issue: 1
  year: 2012
  end-page: 83
  article-title: Nutritional influences on epigenetics and age‐related disease
  publication-title: Proc Nutr Soc
– volume: 27
  start-page: 529
  issue: 3
  year: 2018
  end-page: 547
  article-title: Therapeutic potential of NAD‐boosting molecules: the in vivo evidence
  publication-title: Cell Metab
– volume: 4
  start-page: 214
  issue: 3
  year: 2021
  end-page: 220
  article-title: Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging
  publication-title: Aging Med
– volume: 160
  start-page: 143
  issue: 2
  year: 2014
  article-title: Erratum: stop wasting money on vitamin and mineral supplements (Annals of Internal Medicine (2013) 159 (850–851))
  publication-title: Ann Intern Med
– volume: 11
  start-page: 2874
  issue: 9
  year: 2019
  end-page: 2888
  article-title: Metformin induces a fasting‐ and antifolate‐mimicking modification of systemic host metabolism in breast cancer patients
  publication-title: Aging
– volume: 90
  start-page: 221
  year: 2018
  end-page: 308
  article-title: Telomerase and ageing
  publication-title: Subcell Biochem
– volume: 8
  issue: 2
  year: 2013
  article-title: Curcumin modulates DNA methylation in colorectal cancer cells
  publication-title: PLoS One
– volume: 17
  start-page: 249
  issue: 3
  year: 1994
  end-page: 258
  article-title: Superoxide dismutase, aging, and degenerative disease
  publication-title: Free Radic Biol Med
– volume: 30
  start-page: 251
  issue: 2
  year: 2019
  end-page: 294
  article-title: Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age‐related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes
  publication-title: Antioxid Redox Signal
– volume: 22
  start-page: 895
  issue: 5
  year: 2015
  end-page: 906
  article-title: A comprehensive analysis of replicative lifespan in 4,698 single‐gene deletion strains uncovers conserved mechanisms of aging
  publication-title: Cell Metab
– volume: 40
  start-page: 463
  issue: 6
  year: 2013
  end-page: 471
  article-title: An estimation of the number of cells in the human body
  publication-title: Ann Hum Biol
– volume: 25
  start-page: 516
  issue: 4
  year: 2013
  end-page: 522
  article-title: Thymic rejuvenation and aging
  publication-title: Curr Opin Immunol
– volume: 171
  start-page: 190
  issue: 3
  year: 2019
  end-page: 198
  article-title: Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map
  publication-title: Ann Intern Med
– ident: e_1_2_9_30_1
  doi: 10.1038/S41591‐019‐0673‐2
– ident: e_1_2_9_46_1
  doi: 10.1038/s41586‐018‐0645‐6
– ident: e_1_2_9_25_1
  doi: 10.1016/j.cub.2018.04.015
– ident: e_1_2_9_42_1
  doi: 10.1016/0891‐5849(94)90080‐9
– ident: e_1_2_9_44_1
  doi: 10.1016/J.MOLCEL.2016.01.028
– ident: e_1_2_9_32_1
  doi: 10.1089/rej.2017.2024
– ident: e_1_2_9_36_1
  doi: 10.1186/S13287‐019‐1165‐5
– ident: e_1_2_9_41_1
  doi: 10.1093/JN/134.3.489
– ident: e_1_2_9_45_1
  doi: 10.1016/j.cmet.2018.02.011
– ident: e_1_2_9_38_1
  doi: 10.1016/J.COI.2013.06.002
– ident: e_1_2_9_9_1
  doi: 10.1111/ACEL.13028
– ident: e_1_2_9_40_1
  doi: 10.1016/j.cmet.2016.05.022
– ident: e_1_2_9_7_1
  doi: 10.3390/genes9030165
– ident: e_1_2_9_3_1
  doi: 10.3389/FPUBH.2017.00335
– ident: e_1_2_9_48_1
  doi: 10.1016/J.CHEMBIOL.2009.12.001
– ident: e_1_2_9_12_1
  doi: 10.1016/J.JACC.2018.04.020
– ident: e_1_2_9_26_1
  doi: 10.18632/aging.101590
– ident: e_1_2_9_31_1
  doi: 10.1073/pnas.1814723116
– ident: e_1_2_9_23_1
  doi: 10.1042/BST0321006
– ident: e_1_2_9_5_1
  doi: 10.1159/000484629
– ident: e_1_2_9_2_1
  doi: 10.7326/M19‐0341
– ident: e_1_2_9_13_1
  doi: 10.1038/nrm.2016.93
– ident: e_1_2_9_43_1
  doi: 10.1016/S0891‐5849(00)00317‐8
– ident: e_1_2_9_49_1
  doi: 10.18632/aging.103418
– ident: e_1_2_9_19_1
  doi: 10.1371/journal.pone.0057709
– ident: e_1_2_9_20_1
  doi: 10.3390/nu11061251
– ident: e_1_2_9_27_1
  doi: 10.18632/AGING.101960
– ident: e_1_2_9_29_1
  doi: 10.1093/GERONA/GLT190
– ident: e_1_2_9_37_1
  doi: 10.1038/s41586‐020‐2975‐4
– ident: e_1_2_9_4_1
  doi: 10.1016/j.cell.2012.01.003
– ident: e_1_2_9_16_1
  doi: 10.3390/ANTIOX4040793
– ident: e_1_2_9_22_1
  doi: 10.1080/15592294.2015.1013792
– ident: e_1_2_9_14_1
  doi: 10.7326/L14‐5001‐8
– ident: e_1_2_9_35_1
  doi: 10.1016/j.cmet.2015.09.008
– ident: e_1_2_9_17_1
  doi: 10.1002/agm2.12170
– ident: e_1_2_9_47_1
  doi: 10.1007/978‐981‐13‐2835‐0_9
– ident: e_1_2_9_39_1
  doi: 10.1089/ARS.2017.7269
– ident: e_1_2_9_8_1
  doi: 10.1126/science.aac4854
– ident: e_1_2_9_21_1
  doi: 10.2217/epi.11.22
– ident: e_1_2_9_33_1
  doi: 10.18203/2349‐3259.IJCT20161408
– ident: e_1_2_9_28_1
  doi: 10.1093/CARCIN/BGV031
– volume: 25
  start-page: 3011
  issue: 4
  year: 2005
  ident: e_1_2_9_10_1
  article-title: Telomere attrition as ageing biomarker
  publication-title: Anticancer Res
– ident: e_1_2_9_11_1
  doi: 10.1091/mbc.E18‐10‐0650
– ident: e_1_2_9_18_1
  doi: 10.1017/S0029665111003302
– ident: e_1_2_9_6_1
  doi: 10.3109/03014460.2013.807878
– ident: e_1_2_9_15_1
  doi: 10.7326/0003‐4819‐142‐1‐200501040‐00110
– ident: e_1_2_9_24_1
  doi: 10.1016/j.arr.2016.10.005
– ident: e_1_2_9_34_1
  doi: 10.1016/J.ARR.2019.02.003
SSID ssj0001999632
Score 2.192825
SecondaryResourceType review_article
Snippet Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered out of...
Abstract Aging is widely considered an immovable fact of life. Cultural conditioning has ensured that therapeutics for extreme human lifespans are considered...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 68
SubjectTerms Aging
aging, experimental, gerontology, health industry, longevity industry
Biomarkers
Classification
Diet
Dietary minerals
Disease prevention
DNA methylation
Exercise
Fasting
Genomes
Lifestyles
Mortality
Review
Vitamins
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB4hDqWXCvoM0MoVXFo1IvEjj962VSlC2p6oxM2yHZsibbOIsiD-Db-FX8aME6KNiuilUg5RPFIsz9jzjT3-BmBXSGyoXZEGp6pU5k2Z2tz4tC4qX4daiVDT3eHpj-Lgpzw8VsdLpb4oJ6yjB-4Gbq9Ah5Z7SSQjThqX2VI2ljtlauuKTEYmUHRjS8FU3F0hHC_4wEfK98zJb05UCrUYeaBI1P8Quvw7SXJt0Z6Z6yszm42BbPRE--vwrIeQbNJ1fQNWfPscnkz7Q_IX0KDq2elSLiPDJxYjYh1v82c2YY5QM6UJRc2wWBDnE0M0eHtz7ik7OG4bMoS0LOCCyNr5pZ8xSp86mVN0_RKO9r8dfT1I-2IKqSNMlOa-4l45LwPGIIVvGhkylTmHM145zuuQG2sM0YLG-6eqykJlBcIJK63DSPYVrLbz1r8BxnNqyY0SJkgUtS4YkfnSO1MG7mUCH-7HV7ueaJzqXcx0R5HMNelCR10ksDPInnX0Gg9KfSE1DRJEiR0_oKHo3lD0vwwlge17Jet-nv7RvCCGQqIkSuD90IwzjI5NTOvnC5JBkEMOhSfwurOJoSdCCfytKhIoR9Yy6uq4pT39FVm8KwyUcb1MYHewq0eH4GM0uUdE9OT7lMe3zf8xXlvwlNNVj5hvtw2rF-cL_xYB2IV9F-faHezpLkE
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Proquest Health and Medical Complete
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSNAL4t1AQUb0AiJq4kceXNCCKBXScirS3izbsZdK22S77YL67zvjeFMiqpVyiOKR4mRm7G_s8TeEHHABDbUtUm9llYq8KVOTa5fWReVqX0vuazw7PP1ZHP8SP2ZyFhfcLmJa5WZMDAN101lcIz9kBXLJIXnM5-V5ilWjcHc1ltC4S-7lAFXQqstZebPGgmies4GVlB3q-RlDQoWaj-ahQNd_G8b8P1Xywbpd6qu_erEYw9kwHx09Ig8jkKSTXvOPyR3XPiH3p3Gr_CmxYAD09J-MRgpXKElEe_bmT3RCLWJnTBYK-qGhLM5HCpiQrhymCIe1Qwq4lnoYFWnb_XELijlU8w5D7Gfk5OjbydfjNFZUSC0CozR3FXPSOuEhEClc0wifycxacHtpGat9ro3WyA0aDqHKKvOV4YApjDAWwtnnZKftWrdHKMuxJdeSay9A1FiveeZKZ3XpmRMJeb_5vcpGtnEserFQPU8yU6gKFVSRkHeD7LLn2LhV6gtqaZBAXuzwoFvNVXQzVQD8yZ1AShortM1MKRrDrNS1sUUmoFv7Gx2r6KwX6sa0EvJ2aAY3w70T3bpujTKAdHBWYQl50ZvE0BMuObxWFgkpR8Yy6uq4pT39Hai8K4iWYdBMyMFgVlt_wYdgcVtE1OT7lIW7l9s_9RXZZXiSI6TT7ZOdy9XavQZ8dWneBCe6Bn28JN8
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFD_MCboX8XvVKRH3oljWpkk_xJerOIdwxYcJewtJmlwHd-2425343-xv2V_mOWlvr8UxEPpQmlMaej7yS3LyOwC7mcCGyuaxt7KMRVoXsUm1i6u8dJWvZOYrOjs8_ZYf_BBfj-TRBnxYnYXp-CGGBTfyjBCvycG1Odtbk4bq2QknboQquwW3Uxr2iddZfF-vsBCWDxXKuChkjKE6GfhJ-d769dGIFIj7r0Ob_yZN3l02p_r3Lz2fj4FtGJn278O9HlKySWcDD2DDNQ_hzrTfNH8ENZoCO_4rt5HhFYoTsY7H-T2bMEsomtKGgqZYKJDzjiE6vLpcOMoWDsuIDCEu8xggWdNeuDmjdKpZS7Ptx3C4__nw00HcF1eILWGkOHUld9I64XFOkru6Fj6RibUYAaTlvPKpNloTTWg4jyrLxJcmQ3hhhLE4s30Cm03buG1gPKWWVMtMe4GixnqdJa5wVheeOxHBm9X_VbYnHqf6F3PVUSZzRbpQQRcRvB5kTzu6jWulPpKaBgmiyA4P2sVM9R6nckRCqRPETmOFtokpRG24lboyNk8EdmtnpWTV--2Z4jkxFhJFUQSvhmb0ONpG0Y1rlySDoIcGGB7B084mhp5kMsPPyjyCYmQto66OW5rjn4HVu8SJM8bPCHYHu7rxF7wNJneDiJp8mfJw9-x_hJ_DFqcjHiHPbgc2zxdL9wKB17l5GfzrD288KH0
  priority: 102
  providerName: Wiley-Blackwell
Title The intervention on aging system: A classification model, the requirement for five novel categories
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fagm2.12193
https://www.ncbi.nlm.nih.gov/pubmed/35309156
https://www.proquest.com/docview/2638171154
https://www.proquest.com/docview/2641514672
https://pubmed.ncbi.nlm.nih.gov/PMC8917257
https://doi.org/10.1002/agm2.12193
https://doaj.org/article/60911e49028c4ac0b74db2c5a9bc6044
UnpaywallVersion publishedVersion
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals - NZ
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: DOA
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: M~E
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: RPM
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVOVD
  databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: OVEED
  dateStart: 20180601
  isFulltext: true
  titleUrlDefault: http://ovidsp.ovid.com/
  providerName: Ovid
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: BENPR
  dateStart: 20180601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Proquest Health and Medical Complete
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: 7X7
  dateStart: 20180601
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVWIB
  databaseName: KBPluse Wiley Online Library: Open Access
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: AVUZU
  dateStart: 20180601
  isFulltext: true
  titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Open Access
  customDbUrl:
  eissn: 2475-0360
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999632
  issn: 2475-0360
  databaseCode: 24P
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwED5trQR84f0lMCoD-wIiI3HsvPCtmzYmpFYVWlHhS2S7zjatpNNoQfBr-C38Mu6cNFpgqpCiJIoviWOfz4_j83MA25HAhMzEfmFk6otwmvg6VNbP4tRmRSajIqO1w4NhfDgW7ydysgHPV2th2vP3_I06_sKJASGLNqEb0yRSB7rj4aj_iaLGiUT6aIKDhnf08g2tnsYR8l-FIv91hry-LM_Vj-9qNmsDVtfjHNyCvVVeK0eTs53lQu-Yn3_ROK7_mNtwswacrF9pyB3YsOVduDaop9TvwRQVhZ1e8nxkuLnQRaxieX7L-swQxianIlePzIXPec0QO_7-dWHJl9j9ZGQIgFmB5pOV8292xsjZ6nhOY_H7cHSwf7R36NehF3xDCMoPbcqtNFYUOGKJ7XQqikAGxqB9kIbzrAiVVopIRN1qVZkGRaojBB9aaIPj3gfQKeelfQSMh5QSKhmpQqCoNoWKAptYo5KCW-HBy1Ut5aamJafoGLO8IlTmOZVa7krNgxeN7HlFxnGl1C5VdiNBBNruAlZFXrfHPEacFFpB3DVGKBPoREw1N1Jl2sSBwGxtrVQlr1v115zHxGdIBEYePGuSsT3SJIsq7XxJMgiJqPvhHjysNKvJSSQjfK2MPUhaOtfKajulPD1xnN8pDqvRunqw3Wjn2iJ45RR3jUjefzfg7uzx_z3zCdzgtPTD-d9tQWdxsbRPEZAtdA82uRjhPpkkPej2P44_j_G4uz8cfei5nxy9us3-Ab5SOIk
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VIlEuiDcLBYwoBxCr7nrtfSAhFB4lpU1PQcrN8jp2qBR2Q9pQ9UfxH5nxbrZEVLlVyiGKR8nG89n-xh5_A7CTCGwoTBo6I_NQxOMsLGNtwyLNbeEKmbiC7g4PjtL-d_FtJEcb8Gd5F4bSKpdzop-ox7WhPfJdnpKWHInHfJj9CqlqFJ2uLktoNLA4sOdnGLKdvN__jP59xfnel-GnfthWFQgNkYMwtjm30ljhkIyndjwWLpKRMQh9aTgvXKxLrUkf01_ElHnk8jLBdbUUpcGQDr_2GlwXSSRIqj8bZRdbOhQ8JLwTQeW7evKTk35Dkawse746wGWU9v_MzK1FNdPnZ3o6XWXPfvnbuw23Wt7Keg3Q7sCGre7CjUF7Mn8PDOKNHf-TQMnw5SsgsUYs-h3rMUNUnXKTPByYr8LzliEFZXNLGcl-q5IhjWYOJ2FW1b_tlFHK1qSmiP4-DK-iqx_AZlVX9hEwHlNLrGWinUDT0jidRDazRmeOWxHA62X3KtOKm1ONjalqZJm5Ilco74oAXna2s0bS41Krj-SlzoJkuP0H9Xyi2lGtUmRbsRWkgGOENlGZiXHJjdRFaVIESADbSx-rdm44URdIDuBF14yjmo5qdGXrBdkgsaJFjAfwsIFE9ySJTPBnZRpAtgKWlUddbamOf3jl8ByDc5yjA9jpYLW2C954xK0xUb2vA-7fPV7_V5_DVn84OFSH-0cHT-Amp0skPpNvGzZP5wv7FKndafnMDygG6ooH8F-BEV-v
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAYviG8CA4wYDyCiJv7IBxJChVE2RiceNqlvluPY3aQuKd3KtD-N_447J82omPo2qQ9VfUpc3539O_v8O0K2uICG3CShMzILRVymYRFrG-ZJZnOXS-5yvDs83E92DsX3kRytkT-LuzCYVrmYE_1EXdYG98h7LEEuOSSP6bk2LeLn9uDT9FeIFaTwpHVRTqMxkT17cQ7h2-nH3W3Q9RvGBl8PvuyEbYWB0CBQCGObMSuNFQ6AeWLLUrhIRsaAG0jDWO5iXWiNXJn-UqbMIpcVHNbYQhQGwjt47A1yM-WCYzZZOkovt3cwkOCsI0RlPT0-YcjlkPOlJdBXCrgK3v6fpXlrXk31xbmeTJaRtF8KB3fJnRbD0n5jdPfImq3uk41he0r_gBiwPXr8TzIlhY-vhkQb4ugPtE8NwnbMU_KmQX1FnvcU4CidWcxO9tuWFCA1dTAh06r-bScU07fGNUb3D8nBdQz1I7Je1ZV9QiiLsSXWkmsnQLQwTvPIptbo1DErAvJ2MbzKtETnWG9johqKZqZQFcqrIiCvO9lpQ-9xpdRn1FIngZTc_od6Nlath6sEkFdsBbLhGKFNVKSiLJiROi9MEgno1uZCx6qdJ07VpVUH5FXXDB6Oxza6svUcZQBk4YLGAvK4MYmuJ1xyeK1MApIuGctSV5dbquMjzyKeQaAO83VAtjqzWjkE77zFrRBR_W9D5r89Xf1XX5INcF31Y3d_7xm5zfA-iU_q2yTrZ7O5fQ4o76x44f2JEnXN_vsXC_tj6g
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VrQS98E8JFGSgFxApiWM7CbelolRIW3FopXKKbMcuFUu2KrsgeBqehSdjxslGDVQrpByizCRx7LH9OTP-BmA7EygorYq9lUUs0jqPTapdXKrClb6UmS9p7_DkQO0fiffH8ngNni73wgz99_yVPvnCiQGhzK7AuiIn0gjWjw4-jD9S1jiRyxiH4KTnHb14w2CmCYT8l6HIf4Mhry2aM_3ju55Oh4A1zDh7N2B3WdY20OTzzmJuduzPv2gcV3_MTbjeAU42bi3kFqy55jZcnXQu9TtQo6Gw0wuRjwyPkLqItSzPr9mYWcLYFFQU2pGF9DkvGWLH37_OHcUSh5-MDAEw8zh8smb2zU0ZBVudzGgtfhcO994e7u7HXeqF2BKCilNXcCetEx5XLMrVtfCJTKzF8UFazkufaqM1kYiG3aqySHxhMgQfRhiL6957MGpmjbsPjKckSbXMtBeoaqzXWeJyZ3XuuRMRPF-2UmU7WnLKjjGtWkJlXlGtVaHWInjW6561ZByXar2hxu41iEA7XMCmqLr-WCnESakTxF1jhbaJyUVtuJW6NFYlAou1tTSVquvVXyuuiM-QCIwieNKLsT-Sk0U3brYgHYRENP3wCDZby-pLkskMXytVBPnA5gZFHUqa00-B87vAZTWOrhFs99a5sgpeBMNdoVKN3014OHvwf898CBuctn6E-LstGM3PF-4RArK5edz1yD-zFzJ-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+intervention+on+aging+system%3A+A+classification+model%2C+the+requirement+for+five+novel+categories&rft.jtitle=Aging+medicine&rft.au=Palmer%2C+Raymond+D&rft.date=2022-03-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=2475-0360&rft.volume=5&rft.issue=1&rft.spage=68&rft.epage=72&rft_id=info:doi/10.1002%2Fagm2.12193&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-0360&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-0360&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-0360&client=summon